Neurocrine expects $20M in revenue milestones under AbbVie pact in FY19

Neurocrine expects $20M in revenue milestones under the AbbVie agreement in FY19  Neurocrine (NBIX) announces revenue milestones under the AbbVie (ABBV) agreement for 2019 are expected to be $20M contingent on FDA’s acceptance of the NDA submission of elagolix for uterine fibroids. Ongoing SG&A and R&D expenses for 2019, excluding upfront expenses associated with the recently announced Voyager Therapeutics collaboration, should approximate $550M-$600M. The 2019 anticipated expenses include an estimated $80M of share-based compensation expense. The increase in expenses is largely attributable to the Voyager collaboration’s ongoing program costs, increased investment in INGREZZA patient education, sales and marketing activities, opicapone NDA submission and increased R&D pipeline activities.
https://thefly.com/landingPageNews.php?id=2859439